Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBITDA: 2022-2025

Historic EBITDA for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$51.1 million.

  • ARS Pharmaceuticals' EBITDA fell 174.15% to -$51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.4 million, marking a year-over-year decrease of 65.39%. This contributed to the annual value of $8.2 million for FY2024, which is 114.93% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported EBITDA of -$51.1 million as of Q3 2025, which was down 13.58% from -$45.0 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' EBITDA registered a high of $49.8 million during Q4 2024, and its lowest value of -$51.1 million during Q3 2025.
  • Over the past 3 years, ARS Pharmaceuticals' median EBITDA value was -$15.3 million (recorded in 2023), while the average stood at -$16.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 815.94% in 2024, then crashed by 258.95% in 2025.
  • ARS Pharmaceuticals' EBITDA (Quarterly) stood at -$14.0 million in 2022, then skyrocketed by 50.38% to -$7.0 million in 2023, then surged by 815.94% to $49.8 million in 2024, then slumped by 174.15% to -$51.1 million in 2025.
  • Its last three reported values are -$51.1 million in Q3 2025, -$45.0 million for Q2 2025, and -$34.1 million during Q1 2025.